Reaction
Vascular Graft reporting signals
As of the last recalculation, Vascular Graft appears in 2,851 FAERS reports alongside 34 co-occurring drug terms. The strongest observed disproportionality signal is RANOLAZINE (PRR 69.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranolazine | 96 | 69.5 | 70.1 |
| Prasugrel Hydrochloride | 10 | 7.2 | 7.2 |
| Human Insulin | 12 | 7.0 | 7.0 |
| Nitroglycerin | 48 | 6.6 | 6.6 |
| Insulin Glulisine | 9 | 6.5 | 6.5 |
| Alirocumab | 22 | 6.4 | 6.5 |
| Clopidogrel | 165 | 6.4 | 6.4 |
| Ezetimibe And Simvastatin | 13 | 6.3 | 6.3 |
| Niacin | 9 | 5.7 | 5.7 |
| Insulin Human | 29 | 5.4 | 5.4 |
| Insulin Aspart | 47 | 5.3 | 5.3 |
| Insulin Glargine-Yfgn | 15 | 5.0 | 5.0 |
| Metoprolol Tartrate | 176 | 4.9 | 4.9 |
| Metoprolol Succinate | 56 | 4.8 | 4.8 |
| Sitagliptin And Metformin Hydrochloride | 14 | 4.8 | 4.8 |
| Insulin Glargine | 149 | 4.6 | 4.6 |
| Isosorbide Mononitrate | 13 | 4.6 | 4.6 |
| Evolocumab | 98 | 4.5 | 4.5 |
| Atorvastatin Calcium | 147 | 4.5 | 4.5 |
| Fluticasone Propionate And Salmeterol | 24 | 4.2 | 4.2 |
| Umeclidinium | 5 | 4.1 | 4.1 |
| Empagliflozin | 37 | 4.1 | 4.1 |
| Patiromer | 7 | 3.7 | 3.7 |
| Risankizumab-Rzaa | 40 | 3.6 | 3.6 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 8 | 3.5 | 3.5 |
| Dofetilide | 5 | 3.5 | 3.5 |
| Alteplase | 7 | 3.4 | 3.4 |
| Insulin Lispro | 56 | 3.0 | 3.0 |
| Ticagrelor | 13 | 3.0 | 3.0 |
| Relugolix | 9 | 2.8 | 2.8 |
| Liraglutide | 16 | 2.4 | 2.4 |
| Ranibizumab | 7 | 1.9 | 1.9 |
| Aflibercept | 7 | 1.6 | 1.6 |
| Cinacalcet Hydrochloride | 9 | 1.4 | 1.4 |